Immunological GABAergic interactions and therapeutic applications in autoimmune diseases

Autoimmunity Reviews

Volumn 14, Issue 11, 2015, Pages 1048-1056

  Prud'homme, Gérald J ^a,b   Glinka, Yelena ^b   Wang, Qinghua ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c FUDAN UNIVERSITY   (China)

Author keywords

Diabetes; EAE; GABA; GAD65; Immunotherapy; Inflammation; Ion channel

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT;

APOPTOSIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM SIGNALING; CELL PROLIFERATION; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DERMATITIS; DRUG EFFECT; ENCEPHALITIS; EPILEPSY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GABAERGIC SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RODENT; STIFF MAN SYNDROME; T LYMPHOCYTE; VACCINATION; ANIMAL; AUTOIMMUNE DISEASES; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GAMMA-AMINOBUTYRIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; RECEPTORS, GABA;

EID: 84941260909     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.011     Document Type: Review

References (118)

1. Taniguchi H., Okada Y., Seguchi H., Shimada C., Seki M., Tsutou A., et al. High concentration of gamma-aminobutyric acid in pancreatic beta cells. Diabetes 1979, 28(7):629-633.
2. Bhat R., Axtell R., Mitra A., Miranda M., Lock C., Tsien R.W., et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A 2010, 107(6):2580-2585.
3. Tian J., Lu Y., Zhang H., Chau C.H., Dang H.N., Kaufman D.L. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol 2004, 173:5298-5304.
4. Bjurstöm H., Wang J., Ericsson I., Bengtsson M., Liu Y., Kumar-Mendu S., et al. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol 2008, 205(1-2):44-50.
5. Alam S., Laughton D.L., Walding A., Wolstenholme A.J. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol Immunol 2006, 43(9):1432-1442.
6. Dionisio L., José De Rosa M., Bouzat C., Esandi Mdel C. An intrinsic GABAergic system in human lymphocytes. Neuropharmacology 2011, 60(2-3):513-519.
7. Mendu S.K., Bhandage A., Jin Z., Birnir B. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. PLoS One 2012, 7(8):e42959.
8. Xu E., Kumar M., Zhang Y., Ju W., Obata T., Zhang N., et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 2006, 3(1):47-58.
9. Wang Q., Liang X., Wang S. Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front Physiol 2012, 3:485.
10. Braun M., Ramracheya R., Bengtsson M., Clark A., Walker J.N., Johnson P.R., et al. Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells. Diabetes 2010, 59(7):1694-1701.
11. Soltani N., Qiu H., Aleksic M., Glinka Y., Zhao F., Liu R., et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A 2011, 108(28):11692-11697.
12. Wan Y., Wang Q., Prud'homme G.J. GABAergic system in the endocrine pancreas: a new target for diabetes treatment. Diabetes Metab Syndr Obes 2015, 8:79-87.
13. Buddhala C., Hsu C.C., Wu J.Y. A novel mechanism for GABA synthesis and packaging into synaptic vesicles. Neurochem Int 2009, 55(1-3):9-12.
14. Chessler S.D., Lernmark A. Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues. J Biol Chem 2000, 275(7):5188-5192.
15. Yoon J.W., Yoon C.S., Lim H.W., Huang Q.Q., Kang Y., Pyun K.H., et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science May 14 1999, 284(5417):1183-1187.
16. Tillakaratne N.J., Medina-Kauwe L., Gibson K.M. Gamma-aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comp Biochem Physiol A Physiol 1995, 112(2):247-6.
17. Gasnier B. The loading of neurotransmitters into synaptic vesicles. Biochimie 2000, 82(4):327-337.
18. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011, 10(9):685-697.
19. Chebib M., Johnston G.A. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 2000, 43(8):1427-1447.
20. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008, 60(3):243-260.
21. Bettler B., Kaupmann K., Mosbacher J., Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004, 84(3):835-867.
22. Furr-Stimming E., Boyle A.M., Schiess M.C. Spasticity and intrathecal baclofen. Semin Neurol 2014, 34(5):591-596.
23. Greenfield L.J. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure 2013, 22(8):589-600.
24. Delgado-Lezama R., Loeza-Alcocer E., Andrés C., Aguilar J., Guertin P.A., Felix R. Extrasynaptic GABA(A) receptors in the brainstem and spinal cord: structure and function. Curr Pharm Des 2013, 19(24):4485-4497.
25. Jin Z., Mendu S.K., Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids 2013, 45(1):87-94.
26. Tian J., Chau C., Hales T.G., Kaufman D.L. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol 1999, 96(1):21-28.
27. Bjork J.M., Moeller F.G., Kramer G.L., Kram M., Suris A., Rush A.J., et al. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 2001, 101(2):131-136.
28. Reyes-García M.G., Hernández-Hernández F., Hernández-Téllez B., García-Tamayo F. GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production. J Neuroimmunol 2007, 188(1-2):64-68.
29. Mendu S.K., Akesson L., Jin Z., Edlund A., Cilio C., Lernmark A., et al. Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. Mol Immunol 2011, 48(4):399-407.
30. Barragan A., Weidner J.M., Jin Z., Korpi E.R., Birnir B. GABAergic signalling in the immune system. Acta Physiol (Oxf) 2015, 213(4):819-827.
31. Fuks J.M., Arrighi R.B., Weidner J.M., Kumar Mendu S., Jin Z., et al. GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog 2012, 8(12):e1003051.
32. Wheeler D.W., Thompson A.J., Corletto F., Reckless J., Loke J.C., Lapaque N., et al. Anaesthetic impairment of immune function is mediated via GABA(A) receptors. PLoS One 2011, 6(2):e17152.
33. Rane M.J., Gozal D., Butt W., Gozal E., Pierce W.M., Guo S.Z., et al. Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusion. J Immunol 2005, 174(11):7242-7249.
34. Prud'homme G.J., Glinka Y., Hasilo C., Paraskevas S., Li X., Wang Q. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation 2013, 96(7):616-623.
35. Lewis R.S., Cahalan M.D. Potassium and calcium channels in lymphocytes. Annu Rev Immunol 1995, 13:623-653.
36. Lai Z.F., Chen Y.Z., Nishi K. Modulation of intracellular Cl-homeostasis by lectin-stimulation in Jurkat T lymphocytes. Eur J Pharmacol 2003, 482(1-3):1-8.
37. Kerschbaum H.H., Negulescu P.A., Cahalan M.D. Ion channels, Ca2+ signaling, and reporter gene expression in antigen-specific mouse T cells. J Immunol 1997, 159(4):1628-1638.
38. Prud'homme G.J., Glinka Y., Udovyk O., Hasilo C., Paraskevas S., Wang Q. GABA protects pancreatic beta cells against apoptosis by increasing SIRT1 expression and activity. Biochem Biophys Res Commun 2014, 452(3):649-654.
39. Yang H., Zhang W., Pan H., Feldser H.G., Lainez E., Miller C., et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 2012, 7(9):e46364.
40. Padgett L.E., Broniowska K.A., Hansen P.A., Corbett J.A., Tse H.M. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013, 1281:16-35.
41. Bending D., Zaccone P., Cooke A. Inflammation and type one diabetes. Int Immunol 2012, 24(6):339-346.
42. Cockfield S.M., Ramassar V., Urmson J., Halloran P.F. Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-gamma. J Immunol 1989, 142(4):1120-1128.
43. Prud'homme G.J., Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999, 6(5):771-777.
44. Koulmanda M., Bhasin M., Hoffman L., Fan Z., Qipo A., Shi H., et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 2008, 105(42):16242-16247.
45. Eldor R., Abel R., Sever D., Sadoun G., Peled A., Sionov R., et al. Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on allogeneic pancreatic islet graft survival. PLoS One 2013, 8(2):e56924.
46. Ding X., Wang X., Xue W., Tian X., Li Y., Jiao F., et al. Blockade of the nuclear factor kappa B pathway prolonged islet allograft survival. Artif Organs 2012, 36(3):E21-E27.
47. Zhao Y., Krishnamurthy B., Mollah Z.U., Kay T.W., Thomas H.E. NF-κB in type 1 diabetes. Inflamm Allergy Drug Targets 2011, 10(3):208-217.
48. Yadav M., Louvet C., Davini D., Gardner J.M., Martinez-Llordella M., Bailey-Bucktrout S., et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012, 209(10):1713-1722. [S1-19].
49. Weiss J.M., Bilate A.M., Gobert M., Ding Y., de Lafaille MA Curotto, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012, 209(10):1723-1742. [S1].
50. Tian J., Dang H.N., Yong J., Chui W.S., Dizon M.P., Yaw C.K., et al. Oral treatment with γ-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One 2011, 6(9):e25338.
51. Tian J., Dang H., Kaufman D.L. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice. PLoS One 2011, 6(9):e25337.
52. Bruni A., Gala-Lopez B., Pepper A.R., Abualhassan N.S., Shapiro A.J. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes 2014, 7:211-223.
53. Khosravi-Maharlooei M., Hajizadeh-Saffar E., Tahamtani Y., Basiri M., Montazeri L., Khalooghi K., et al. Islet transplantation for type 1 diabetes: so close and yet so far away. Eur J Endocrinol Jun 2 2015, [pii: EJE-15-0094. [Epub ahead of print]].
54. Watson C.J. The current challenges for pancreas transplantation for diabetes mellitus. Pharmacol Res 2015, 98:45-51.
55. Purwana I., Zheng J., Li X., Deurloo M., Son D.O., Zhang Z., et al. GABA promotes human β-cell proliferation and modulates glucose homeostasis. Diabetes 2014, 63(12):4197-4205.
56. Johnson J.D., Ao Z., Ao P., Li H., Dai L.J., He Z., et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant 2009, 18(8):833-845.
57. Robinson A.P., Harp C.T., Noronha A., Miller S.D. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol 2014, 122:173-189.
58. Carmans S., Hendriks J.J., Slaets H., Thewissen K., Stinissen P., Rigo J.M., et al. Systemic treatment with the inhibitory neurotransmitter γ-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses. J Neuroimmunol 2013, 255(1-2):45-53.
59. Wang Y., Feng D., Liu G., Luo Q., Xu Y., Lin S., et al. Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J Immunol 2008, 181(12):8226-8236.
60. Wang Y., Luo Q., Xu Y., Feng D., Fei J., Cheng Q., et al. Gamma-aminobutyric acid transporter 1 negatively regulates T cell activation and survival through protein kinase C-dependent signaling pathways. J Immunol 2009, 183(5):3488-3495.
61. Tian J., Yong J., Dang H., Kaufman D.L. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 2011, 44(6):465-470.
62. Huang S., Mao J., Wei B., Pei G. The anti-spasticity drug baclofen alleviates collagen-induced arthritis and regulates dendritic cells. J Cell Physiol 2015, 230(7):1438-1447.
63. Nigam R., El-Nour H., Amatya B., Nordlind K. GABA and GABA(A) receptor expression on immune cells in psoriasis: a pathophysiological role. Arch Dermatol Res 2010, 302(7):507-515.
64. Boyd S.T., Mihm L., Causey N.W. Improvement in psoriasis following treatment with gabapentin and pregabalin. Am J Clin Dermatol 2008, 9(6):419.
65. Duthey B., Hübner A., Diehl S., Boehncke S., Pfeffer J., Boehncke W.H. Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol 2010, 19(7):661-666.
66. Baizabal-Carvallo J.F., Jankovic J. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry Dec 15 2014, [pii: jnnp-2014-309201, [Epub ahead of print]]. 10.1136/jnnp-2014-309201.
67. Dayalu P., Teener J.W. Stiff person syndrome and other anti-GAD-associated neurologic disorders. Semin Neurol 2012, 32(5):544-549.
68. Dinkel K., Meinck H.M., Jury K.M., et al. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998, 44:194-201.
69. Gu Urban G.J., Friedman M., Ren P., Törn C., Fex M., Hampe C.S., et al. Elevated serum GAD65 and GAD65-GADA immune complexes in stiff person syndrome. Sci Rep 2015, 5:11196.
70. Manto M., Honnorat J., Hampe C.S., Guerra-Narbona R., López-Ramos J.C., Delgado-García J.M., et al. Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. Front Behav Neurosci 2015, 9:78.
71. Werner .C, Haselmann H., Weishaupt A., Toyka K.V., Sommer C., Geis C. Stiff person-syndrome IgG affects presynaptic GABAergic release mechanisms. J Neural Transm 2015, 122(3):357-362.
72. Chang T., Alexopoulos H., McMenamin M., Carvajal-González A., Alexander S.K., Deacon R., et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 2013, 70(9):1140-1149.
73. Hansen N., Grünewald B., Weishaupt A., Colaço M.N., Toyka K.V., Sommer C., et al. Human stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol 2013, 239:202-209.
74. Alexopoulos H., Dalakas M.C. Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol 2013, 9(11):1043-1053.
75. Petit-Pedrol M., Armangue T., Peng X., Bataller L., Cellucci T., Davis R., et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014, 13(3):276-286.
76. Lernmark A., Larsson H.E. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013, 9(2):92-103.
77. Raju R., Rakocevic G., Chen Z., Hoehn G., Semino-Mora C., Shi W., et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006, 129:3270-3276.
78. Chéramy M., Hampe C.S., Ludvigsson J., Casas R. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals. Clin Exp Immunol 2013, 171:247-254.
79. Daw K., Ujihara N., Atkinson M., Powers A.C. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996, 156:818-825.
80. Butler M.H., Solimena M., Dirkx R., Hayday A., De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993, 178:2097-2106.
81. Raju R., Hampe C.S. Immunobiology of stiff-person syndrome. Int Rev Immunol 2008, 27(1-2):79-92.
82. Murinson B.B., Guarnaccia J.B. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008, 71(24):1955-1958.
83. McKeon A., Robinson M.T., McEvoy K.M., Matsumoto J.Y., Lennon V.A., Ahlskog J.E., et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol 2012, 69(2):230-238.
84. Miller F., Korsvik H. Baclofen in the treatment of stiff-man syndrome. Ann Neurol 1981, 9:511-512.
85. Zdziarski P. A case of stiff person syndrome: immunomodulatory effect of benzodiazepines: successful rituximab and tizanidine therapy. Medicine (Baltimore) 2015, 94(23):e954.
86. Toledano M., Pittock S.J. Autoimmune epilepsy. Semin Neurol 2015, 35(3):245-258.
87. Hainsworth J.B., Shishido A., Theeler B.J., Carroll C.G., Fasano R.E. Treatment responsive GABA(B)-receptor limbic encephalitis presenting as new-onset super-refractory status epilepticus (NORSE) in a deployed U.S. soldier. Epileptic Disord 2014, 16(4):486-493.
88. Holzer F.J., Seeck M., Korff C.M. Autoimmunity and inflammation in status epilepticus: from concepts to therapies. Expert Rev Neurother 2014, 14(10):1181-1202.
89. Suleiman J., Dale R.C. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol 2015, 57(5):431-440.
90. Dubey D., Konikkara J., Modur P.N., Agostini M., Gupta P., Shu F., et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disord 2014, 16(4):494-499.
91. Wan X., Zaghouani H. Antigen-specific therapy against type 1 diabetes: mechanisms and perspectives. Immunotherapy 2014, 6(2):155-164.
92. Simmons K.M., Michels A.W. Type 1 diabetes: a predictable disease. World J Diabetes 2015, 6(3):380-390.
93. Arvan P., Pietropaolo M., Ostrov D., Rhodes C.J. Islet autoantigens: structure, function, localization, and regulation. Cold Spring Harb Perspect Med 2012, 2(8).
94. Fierabracci A. Peptide immunotherapies in type 1 diabetes: lessons from animal models. Curr Med Chem 2011, 18(4):577-586.
95. Morales A.E., Thrailkill K.M. GAD-alum immunotherapy in type 1 diabetes mellitus. Immunotherapy 2011, 3(3):323-332.
96. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009, 25(4):307-315.
97. Hjorth M., Axelsson S., Rydén A., Faresjö M., Ludvigsson J., Casas R. GAD-alum treatment induces GAD65-specific CD4+ CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol 2011, 138(1):117-126.
98. Ludvigsson J., Krisky D., Casas R., Battelino T., Castaño L., Greening J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366(5):433-442.
99. Glinka Y., Chang Y., Prud'homme G.J. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol Ther 2006, 14(4):578-587.
100. Prud'homme G.J., Draghia-Akli R., Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther Apr 2007, 14(7):553-564.
101. Goudy K.S., Wang B., Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin Immunol 2008, 129(1):49-57.
102. von Herrath M.G., Whitton J.L. DNA vaccination to treat autoimmune diabetes. Ann Med 2000, 32(5):285-292.
103. Baekkeskov S., Lernmark A. Rodent islet cell antigens recognized by antibodies in sera from diabetic patients. Acta Biol Med Ger 1982, 41(12):1111-1115.
104. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., McDevitt H.O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993, 366(6450):72-75.
105. Boettler T., Pagni P.P., Jaffe R., Cheng Y., Zerhouni P., von Herrath M. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes. J Autoimmun 2013, 44:40-48.
106. Kash S.F., Condie B.G., Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm Metab Res 1999, 31(5):340-344.
107. Bridgett M., Cetkovic-Cvrlje M., O'Rourke R., Shi Y., Narayanswami S., Lambert J., et al. Differential protection in two transgenic lines of NOD/Lt mice hyperexpressing the autoantigen GAD65 in pancreatic beta-cells. Diabetes 1998, 47(12):1848-1856.
108. Tian J., Dang H., Nguyen A.V., Chen Z., Kaufman D.L. Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice. Diabetes 2014, 63(9):3128-3134.
109. Beghi E., Shorvon S. Antiepileptic drugs and the immune system. Epilepsia 2011, 52(Suppl. 3):40-44.
110. Vasileiou I., Xanthos T., Koudouna E., Perrea D., Klonaris C., Katsargyris A., et al. Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol 2009, 605(1-3):1-8.
111. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997, 75(3):199-216.
112. Smith M.A., Hibino M., Falcione B.A., Eichinger K.M., Patel R., Empey K.M. Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients. Ann Pharmacother 2014, 48(1):77-85.
113. Marik P.E. Propofol: an immunomodulating agent. Pharmacotherapy 2005, 25(5 Pt 2):28S-33S.
114. Tower D.B. The administration of gamma-aminobutyric acid to man: systemic effects and anticonvulsant actions. Inhibition in the Nervous System and Gamma-Aminobutyric Acid 1960, 562-578. Pergamon Press, Oxford, UK. E. Roberts (Ed.).
115. Cavagnini F., Pinto M., Dubini A., Invitti C., Cappelletti G., Polli E.E. Effects of gamma aminobutyric acid (GABA) and muscimol on endocrine pancreatic function in man. Metabolism 1982, 31(1):73-77.
116. Khumarian N.G., Mamikonian R.S. On the role of gamma aminobutyric acid in the regulation of the level of glycemia in diabetes mellitus. Zh Eksp Klin Med 1967, 7(2):3-9.
117. Powers M. GABA supplementation and growth hormone response. Med Sport Sci 2012, 59:36-46.
118. Powers M.E., Yarrow J.F., McCoy S.C., Borst S.E. Growth hormone isoform responses to GABA ingestion at rest and after exercise. Med Sci Sports Exerc 2008, 40(1):104-110.